Protinhi Therapeutics

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Protinihi Therapeutics is an early-preclinical biotech company and develops novel proprietary antivirals acting as protease inhibitors to treat illnesses with a high unmet medical need (flaviviruses, coronaviruses). We will make those antivirals available as early stage broad-spectrum medication therapeutics and prophylactics in upcoming epidemics/pandemics.
Our lead program will deliver in vivo PoC on dengue ready in Q2-3-2020. The lead compounds show high-selectivity and equipotency on flaviviral proteases. We have discovery stage programs on developing broad-spectrum Corona antivirals funded by non-dilutive programs from Dutch government and EU.
Currently we are raising series-A investment of 8US$ mio to further (pre)clinical development.
Speaker
photo
CEO
Protinhi Therapeutics